Category Archives: Cell Biology

Integrated spatial multiomics reveals fibroblast fate during tissue repair – pnas.org

Tissue fibrosis and its sequelae are associated with 45% of all mortality in the United States (1, 2). In the skin, wound healing is achieved through fibrosis and formation of a scar, which is composed of dense extracellular matrix. Scars are stiff, have poor vascularization, lack normal skin appendages, and accordingly are devoid of the skins native functionality. As a result, scars can result in lifelong disability secondary to disfigurement and dysfunction (3). Fibroblasts are the cells responsible for deposition of scar tissue. While several studies have characterized subtypes of fibroblasts involved in wound healing, the development of novel therapies that foster regeneration (rather than fibrosis) has remained limited because the origins, heterogeneity, and behavior of fibroblasts during tissue repair are not yet comprehensively understood.

Current knowledge of wound biology is largely derived from experiments performed in mice. However, translating cutaneous tissue repair in mice to humans is challenging due to species-specific anatomical differences. The panniculus carnosus is a subdermal muscle layer found throughout the body of mice that substantially contracts in response to wounding, enabling wound closure primarily through contracture of the mouses loose skin. In humans, an analog to this muscle exists only in the neck (the platysma muscle), the hand (palmaris brevis), and the scrotum (dartos muscle). Fibroblast heterogeneity has been previously explored in wound healing using mouse models in which large, unstented wounds (1.5-cm diameter) heal primarily by contraction, with only a small portion in the center healing through reepithelialization and deposition of connective tissue from fibroblasts (the primary mechanism of wound healing in humans) (4, 5). To recapitulate clinically relevant wound healing using mouse models, we utilize a stented wound model, which limits contraction of the panniculus carnosus and thereby mimics the wound healing kinetics of tight-skinned humans (6). Given that local tissue mechanics play a central role in scar formation (79), this model permits us to interrogate fibroblast mechanobiology in a more clinically relevant manner.

Recent advances in sequencing and cell capture technology have enabled the assessment of gene expression with reference to tissue organization using spatial transcriptomics. This approach has only been applied to a limited number of tissue types to date, primarily in the study of tumors, including prostate cancer (10), skin cancer (11, 12), and breast cancer (13), as well as bone marrow (14), joints (15), and brain tissue (16). However, to our knowledge, spatial transcriptomic analysis over time has yet to be applied to characterize wound healing. Moreover, the spatial and temporal distributions of the single-cell chromatin landscapes underlying gene expression have yet to be described.

Here, using transgenic mouse models, we assess the proliferation of local, tissue-resident fibroblast cells in wound healing. By establishing a microsurgical approach to independently isolate fibroblasts from spatially distinct regions within the wound, we interrogate Rainbow-labeled fibroblasts from critical timepoints during the course of wound closure. The Rainbow mouse model is a four-color reporter system that permits precise clonal analysis and lineage tracing. Using this model with phenotype-paired single-cell RNA and ATAC sequencing (scRNA-seq and scATAC-seq), we are able to define the spatial and temporal heterogeneity of wound fibroblasts with unique granularity. Using full-length, plate-based scRNA-seq, we assess the differentiation states of individual cells as they proliferate and migrate from the outer wound region inward (17). By disrupting this process using small molecule inhibition or genetic knockdown of focal adhesion kinase (FAK, Ptk2), we further elucidate the relationship between wound healing fibroblast activation and microenvironmental cues. By integrating our scRNA-seq and scATAC-seq analyses using the recently developed ArchR platform (18), we delineate interrelated changes in chromatin accessibility and gene expression driving wound closure and fibrosis and identify distinct wound fibroblast subpopulations. Furthermore, using CIBERSORTx deconvolution (19) of bulk RNA-seq data, we are able to categorize a putative fibroblast subpopulation-based response to local tissue injury. Finally, we introduce spatial multiomics, combining spatial transcriptomics with paired scRNA-seq and scATAC-seq datasets to impute spatial epigenomic properties and map chromatin accessibility states in the healing wound. Collectively, this work defines the spatial and temporal dynamics of the fibroblast response to injury and provides a multimodal -omics framework for future studies in tissue repair.

To explore the lineage dynamics of wound fibroblasts, we examined stented wound healing using the Rainbow (Rosa26VT2/GK3) mouse model (20). Rainbow mice contain a transgenic four-color reporter construct in the Rosa26 locus. Upon induction with Cre recombinase, the four colors irreversibly recombine such that all progeny cells will have the same color as their parent cells, thereby permitting stochastic lineage tracing and clonal analysis (Fig. 1A). We developed a technique for local induction using activated tamoxifen liposomes (LiTMX) in order to induce reporter recombination exclusively in tissue-resident cells (Fig. 1B) (21). Following injury, local skin fibroblasts were found to proliferate in a linear, polyclonal manner along the cross-sectional wound interface (Fig. 1 C and D), whereas fibroblasts in uninjured skin exhibited minimal clonality (Fig. 1 E and F). These data support the presence of local cells that are activated in response to injury and proliferate polyclonally to fill the wound gap.

Wounding triggers polyclonal proliferation of tissue-resident fibroblasts. (A) Schematic of the Rainbow mouse construct. (B) Schematic showing wound healing model using Rainbow mice with local Cre recombinase induction using 4-hydroxytamoxifen liposomes (LiTMX). (C) Schematic showing a Rainbow wound cross-section. Black dotted line highlights wound scar area; arrows indicate the direction of cellular proliferation during wound healing. Structures are as labeled. (D) Representative confocal image of POD 14 wound cross-sections from Actin-CreERT2::Rosa26VT2/GK3 mice induced locally with LiTMX at the time of wound creation. Thick white dotted lines highlight scar boundaries. Individual Rainbow cell clones are highlighted with thin colored dotted lines. Arrows indicate direction of wound healing. n > 5. (Scale bar, 50 m.) (E) Representative confocal images of unwounded skin from Actin-CreERT2::Rosa26VT2/GK3 mice induced locally with LiTMX. Thick white dotted lines highlight dermal boundaries. Individual Rainbow cell clones are highlighted with thin white dotted lines. n > 5. (Scale bar, 50 m.) (F) Rainbow clone counts in wounds versus uninjured skin. n = 5 per condition. *P < 0.05. (G) Schematic of dorsal, stented, excisional wound healing in the Rainbow mouse model (whole-mount view), with polyclonal proliferation of Rainbow fibroblasts from the outer wound edge inward across time from POD 2 (Left), to POD 7 (Middle), to POD 14 (Right). Black arrows highlight the apparent direction of proliferation. (H) Representative confocal imaging of a POD 14 whole-mounted wound harvested from Actin-CreERT2::Rosa26VT2/GK3 mice showing the polyclonal proliferation of wound fibroblasts radially toward the center of the wound (dark area at center). White arrows highlight the direction of cell proliferation; individual cell clones are highlighted with thin colored dotted lines. Bottom subpanels denote individual Rainbow color contributions to merged image. mCh, membrane (m)Cherry; mOr, mOrange; mCe, mCerulean; eG, eGFP. n > 5. (I) Schematics illustrating microdissection strategy for isolation of inner and outer wound regions (Top), followed by enzymatic separation of the dermal scar from the epi- and hypodermis (Bottom). (J) Heatmap displaying expression data for genes significantly different between POD 7 inner and outer region wound fibroblasts. Legend at Right displays fold change. (K) Gene Ontology (GO) enrichment analysis comparing gene expression data from POD 7 inner and outer region wound fibroblasts. Top shows GO biological processes up-regulated in inner region fibroblasts compared with outer region fibroblasts, while the Bottom shows the same for outer region fibroblasts compared with inner. Top 10 most significant gene sets are displayed for each condition.

Many cell surface and lineage markers have been associated with fibroblasts involved in wound healing, including Pdgfra, Engrailed-1 (En1), and CD26 (Dpp4) (2224). However, we and others have found expression of such markers to be variable throughout wound tissue (SI Appendix, Fig. S1A), suggesting spatial and functional heterogeneity among the fibroblasts that respond to injury. We asked whether there might be one or more fibroblasts activated following injury that could give rise to more diverse downstream fibroblast phenotypes. If so, we wondered whether such cells would be of tissue-resident origin, as suggested by previous studies (2527) (SI Appendix, Fig. S1B), or originate from peripheral circulation. To explore this, we employed transgenic parabiotic mice in conjunction with the splinted excisional wound healing model described above (6) (SI Appendix, Fig. S1C). eGFP donor mice were parabiosed to wild-type (C57BL/6J) mice (SI Appendix, Fig. S1D). A shared blood supply was established by 2 wk after surgery (SI Appendix, Fig. S1E), at which time wounds were made on the dorsum of each wild-type parabiont. Wounds were then harvested at postoperative day (POD) 7 (midway through healing) or POD 14 (when the wound has fully reepithelialized). While systemically infiltrating GFP+ cells were found in wild-type mouse wounds at both timepoints, the overwhelming majority (>80%) of GFP+ cells were also CD45+ and thus of hematopoietic (nonfibroblast) lineage (SI Appendix, Fig. S1F). These data further support the growing body of literature indicating that the fibroblasts responsible for wound healing are local, tissue-resident cells (2527).

Returning to the Rainbow mouse model, we developed a tissue clearing and whole-mount protocol to visualize wound healing biology with the Rainbow mouse (28). Using these methods in conjunction with a ubiquitous Actin-CreERT2 driver, we observed that cells were activated along the wound edge and proliferated inward in a distinct radial pattern (Fig. 1 G and H).

Based on the pattern of clonal proliferation extending from the outer wound edge inward, we developed a microsurgical technique to separately isolate the inner and outer components of the wound dermis (Fig. 1I). We isolated wound fibroblasts from these two regions at POD 7 (midpoint of healing) and unwounded skin for bulk RNA-seq evaluation. Clear differences in the gene expression profiles of inner versus outer wound fibroblasts were identified (Fig. 1 J and K and SI Appendix, Fig. S2 AC), including differences in mechanotransduction and cell cycle pathways. Furthermore, we observed that inner wound fibroblasts were transcriptionally more divergent from uninjured skin than were outer wound fibroblasts (SI Appendix, Fig. S2A). These findings support broad regional differences in the proliferation and activation status of fibroblasts in the healing wound; however, these methods are limited by the lack of granularity inherent in bulk transcriptional analysis.

We evaluated how well several recently published cell surface marker profiles, which define fibroblast subtypes largely based on tissue depth, tracked with the regional differences observed in our study (22). Among fluorescence activated cell sorting (FACS)-isolated, lineage-negative (29), Rainbow wound fibroblasts (Fig. 2A and SI Appendix, Fig. S3A), we found that most cells fell into the putative category of reticular fibroblasts (defined as DLK1+/SCA1) rather than papillary (CD26+/SCA1) or hypodermal (DLK1+//SCA1+) (SI Appendix, Fig. S3B). When we considered inner and outer wound fibroblasts separately, we found that distribution of fibroblast subtypes was not significantly different between these two groups (SI Appendix, Fig. S3C), suggesting that fibroblast subpopulations defined by selective marker profiles are not sufficient to delineate inner versus outer wound fibroblasts, though these can be readily distinguished based on their transcriptional programs even at the bulk tissue level.

Single-cell transcriptomic and chromatin accessibility analyses delineate mechanoresponsive fibroblast subpopulations. (A) Schematic illustrating single-cell (sc) isolation of Rainbow wound fibroblasts from inner and outer wound regions (highlighted with black dotted lines). For scRNA-seq, mCerulean+ fibroblasts were arbitrarily selected from the available Rainbow colors and used for the remaining experiments in this figure. (B) (Left) Uniform manifold approximation and projection (UMAP) embedding showing scRNA-seq data from mouse wound fibroblasts FACS isolated using a lineage-negative sort strategy (29) from POD 2, POD 7, and POD 14, digitally pooled and clustered in a manner agnostic to POD and inner versus outer wound regions. Four unique fibroblast clusters were identified (clusters 1 through 4). Dotted lines highlight individual cluster distributions. (Right) Recoloring of Left UMAP plot based on fibroblast tissue region: inner (black) versus outer (orange). (C) CytoTRACE analysis of scRNA-seq data using the UMAP embedding from F. Shading indicates inner (light gray) versus outer (dark gray) wound regions. (D) Box plots showing the predicted ordering by CytoTRACE for individual cells within the four scRNA-seq clusters. Gray arrow indicates direction of predicted differentiation from scRNA-seq cluster 1 to cluster 4 (which corresponds to outer-to-inner wound region expansion). P value was derived from two-sided Students t test. (E) scATAC-seq evaluation of Rainbow mouse wound fibroblasts isolated in parallel with our scRNA-seq experiments (SI Appendix, Methods), integrated using the ArchR toolkit with default Louvain parameters (18) to delineate four unique multimodal fibroblast clusters. (F) Heatmap of scATAC-seq motifs highlighting key gene loci differentially open or closed in putative fibroblast subpopulations. (G) Genome tracking plots showing scATAC-seq peaks for pseudobulk replicates generated for each cluster. Associations between the peaks with fibrosis and mechanotransduction-related genes (Peak2GeneLinks) are included at the Bottom of each plot. Pale orange shading highlights differentially expressed peaks across the scATAC clusters. All highlighted peaks demonstrated statistically significant differential expression in at least one pairwise comparison (false discovery rate [FDR] <0.1 and fold change [FC] 2).

We sought to better characterize wound fibroblast heterogeneity by examining individual fibroblast transcriptional programs at important functional timepoints in the canonical wound healing process: POD 2, inflammation; POD 7, granulation; and POD 14, complete reepithelialization (healed wound). We conducted plate-based scRNA-seq of lineage-negative fibroblasts isolated based on their expression of Rainbow clone colors from both inner and outer wound regions at each timepoint (Fig. 2A). Four transcriptionally defined fibroblast subpopulations were identified (Fig. 2B), with considerable differences in their distributions between wound regions.

Given our interest in understanding lineage trajectories in the context of wound healing, we assessed the relative differentiation states of these fibroblast populations using CytoTRACE, a computational tool that leverages transcriptional diversity to order cells based on developmental potential (Fig. 2C and SI Appendix, Fig. S4) (17). This analysis identified a lineage trajectory stemming from scRNA-cluster 1, which is characterized by elevated expression of fibroblast markers such as Pdgfra and primarily represented by cells from the outer wound region, extending to scRNA-cluster 4, which is primarily represented by cells from the inner wound (Fig. 2D). These findings suggest that fibroblasts may undergo differentiation as they proliferate from the outer wound inward.

To evaluate the epigenomic changes associated with fibroblast activation and lineage differentiation in wound healing, we conducted a series of scATAC-seq experiments in parallel with our scRNA-seq assays (SI Appendix, Fig. S5 A and B). We identified considerable heterogeneity in accessibility profiles among individual wound fibroblasts, which were clustered into six epigenomically distinct subgroups using the ArchR platform (18) (SI Appendix, Figs. S5 C and D and S6 AD). This partitioning was agnostic to the phenotype of cell origin (i.e., wound region or postoperative day), and all clusters included fibroblasts harvested from multiple timepoints and wound regions. We then performed cross-platform integration to link these scATAC data with our earlier scRNA data (18), resulting in four multimodal clusters characterized by both gene expression and chromatin accessibility profiles (Fig. 2 E and F and SI Appendix, Fig. S6E), which we refer to as ArchR-clusters 1 through 4.

We first examined the epigenomic landscape of the largest subpopulation, ArchR-cluster 1, which showed significantly elevated chromatin accessibility proximal to key fibrosis-related genes such as Col1a1, Acta2, and Pdgfra (Fig. 2G and SI Appendix, Figs. S7 A and B and S8), indicating that these cells are primed for their transcription. We also observed specific accessibility peaks and transcription factor footprinting in association with the FAK (Ptk2) locus and its downstream signaling elements such as Jun, suggesting that these fibroblasts may represent a mechanoresponsive, profibrotic subpopulation. ArchR-cluster 2 was associated with elevated Fn1 and Thbs1 accessibility peaks; ArchR-cluster 3 was characterized by increased accessibility at the Jak2 locus and decreased accessibility at the Fsp1 (S100a4) and Il6st loci; and ArchR-cluster 4 was characterized by increased accessibility at the Ptk2b, Jak1, and Jak3 loci.

In addition to specific peak and motif evaluation, we also employed clusterwide enrichment analysis using the Genomics Regions Enrichment of Annotations Tool (GREAT) (30) (SI Appendix, Fig. S9A). We found significant enrichment for increased fibroblast migration, focal adhesion, and FAK-pathway signaling response elements in ArchR-cluster 1. Furthermore, pseudotime analysis of these integrated scRNAATAC data demonstrated an epigenomic progression from the putatively least-differentiated ArchR-cluster 1 to the remaining cell populations that was driven by mechanical signaling elements (SI Appendix, Fig. S9B).

Based on these findings, we provisionally characterized each subpopulation according to its putative role in the wound healing process: mechanofibrotic (ArchR-cluster 1), activated-responder (ArchR-cluster 2), remodeling (ArchR-cluster 3), and proliferator (ArchR-cluster 4) fibroblasts.

Our laboratory has previously shown that local tissue mechanics are crucial in guiding the response to healing after injury (31), and mechanotransduction signaling pathway elements were found to delineate fibroblast subpopulations in our scRNA and scATAC wound data. To further interrogate the role of local tissue mechanics in wound biology, we applied a small molecule FAK inhibitor (FAKi) to disrupt mechanosensation in stented mouse wounds (SI Appendix, Fig. S10A). Consistent with prior work, we found that FAKi-treated wounds healed at the same rate as untreated wounds (SI Appendix, Fig. S10 B and C) but resulted in significantly smaller and thinner scars composed of less-dense matrix tissue (SI Appendix, Fig. S10 D and E) (32).

To validate our FAKi results, we conducted additional wound healing experiments using Actin-CreERT2::Rosa26VT2/GK3::Ptk2fl/+ and Actin-CreERT2::Rosa26VT2/GK3::Ptk2fl/fl (heterozygous Ptk2fl/+] and homozygous [Ptk2fl/fl] knockout) mice, with local LiTMX induction at the time of wounding (SI Appendix, Fig. S10 AC). We found that these mouse wounds also exhibited fewer scar-like patterns of connective tissue (SI Appendix, Fig. S10E). To further explore these differences, we employed an automated feature extraction algorithm (24) to quantify ultrastructure characteristics of wound tissue sections, which demonstrated that FAKi-treated wound specimens were more similar to unwounded skin than to vehicle-control wounds, including for both mature and immature collagen fiber intensities (SI Appendix, Fig. S10F). Taken together, these findings corroborate that when mechanotransduction is disrupted, wounds heal with thinner scars and connective tissue structure that is more similar to that of unwounded skin.

To understand the transcriptional changes associated with modulation of mechanotransduction in wound healing, we conducted additional RNA-seq experiments comparing fibroblasts isolated from inner and outer regions of FAKi-treated and control wounds. We observed significant changes in the transcriptional programs of FAKi-treated cells and found that regional differences between inner and outer wound fibroblasts were dampened in wounds following FAK inhibition (SI Appendix, Fig. S11 A and B). These results suggest that local tissue mechanics contribute to transcriptional differences between inner and outer wound regions. We found that wound healing fibroblasts showed down-regulation of mechanotransduction- and fibrosis-related pathways with FAKi treatment (SI Appendix, Fig. S11C). We also found that when mechanosignaling was blocked in Rainbow mice using FAKi, or in Ptk2fl/+ or Ptk2fl/fl mice, the linear polyclonal proliferation of fibroblasts that was previously appreciated (Fig. 1H) was disrupted (Fig. 3 AC), with smaller and less ordered Rainbow fibroblast clones.

Clonal proliferation of injury-responsive fibroblasts is dependent on mechanotransduction signaling. (A) Representative confocal images of sectioned Rainbow mouse wound specimens treated with FAKi (Second), FAKfl/+ (Third), or FAKfl/fl (Bottom) compared with vehicle control (Top). Imaris rendering in second column of images highlights individual Rainbow clones. Dermal wound area highlighted with thick white dotted line. n = 5. (Scale bars, 25 m.) (B) Quantitation of average clone size based on Imaris rendering. (C) Wedge sections of representative whole-mount confocal images of Rainbow wound specimens embedded within surrounding wound schematics for vehicle control (Top), FAKi-treated (Second), FAKfl/+ (Third), and FAKfl/fl (Bottom) samples. Corresponding vector analyses are provided to the Right of each subpanel. (D) Schematic illustrating our approach to deconvolve bulk RNA-seq data using our multimodal scRNAATAC construct. Transcriptionally defined cluster labels from scRNA-seq analysis were projected onto the scATAC-seq manifold using an anchor transferbased approach in ArchR as previously described (18) (Left column) to construct four multimodal fibroblast subpopulations. Putative names were assigned to these ArchR-clusters based on integrated functional and temporospatial characteristics. Feature and peak plots, above and below, for FAK (Ptk2) are provided for illustrative purposes (Center column). Deconvolution of bulk RNA-seq specimens representing wound fibroblasts treated with FAKi versus vehicle control (Right column) was then performed using CIBRERSORTx (19) (SI Appendix, Methods). Wound schematics (with silicone ring around the outside, and outer and inner regions indicated) are provided to represent CIBRERSORTx output identifying changes in the percentages of ArchR-cluster 1 (mechanofibrotic) cells in bulk samples over time and with/without FAKi treatment (shown in green). Parallel schematic of corresponding changes in other ArchR-clusters are provided in yellow.

We applied the deconvolution tool CIBERSORTx (19) to estimate the abundance of our four scRNAATAC populations (ArchR-clusters 1 through 4) within bulk RNA-seq data for fibroblasts isolated from POD 7 and POD 14 wounds with or without FAKi treatment (Fig. 3D). We found that the majority of cell estimates across all specimens were attributed to mechanofibrotic ArchR-cluster 1, consistent with its prominent representation in both our scRNA-seq and scATAC-seq datasets. The predicted prevalence of these cells was highest at POD 7 and decreased by POD 14. FAK inhibition resulted in decreased representation of ArchR-cluster 1 fibroblasts at POD 14 for both inner and outer wound samples (compared to control wounds at POD 14), further supporting the mechanosensitivity of the putative mechanofibrotic ArchR-cluster 1 subpopulation.

To further explore the significance of fibroblast heterogeneity in healing wounds, we applied the recently developed 10 Genomics Visium platform to analyze gene expression while retaining tissue spatial information. We optimized and validated a protocol to enable highly reproducible Visium spatial transcriptomic analysis of skin and wounds across the healing process (SI Appendix, Methods). We then conducted spatial transcriptomic analysis on tissue from our stented Rainbow mouse wound healing model at POD 2, 7, and 14, as well as uninjured skin (Fig. 4A).

Spatial transcriptomics applied to wound healing and tracking of fibroblast subpopulations over time and space. (A) Schematic for generating spatial transcriptomics data from splinted excisional wounds using the 10 Genomics Visium protocol. Fresh Rainbow mouse wound tissue was harvested, flash frozen, embedded in optimal cutting temperature (OCT), and then sections were taken representing the complete wound radius. H&E staining and tissue section imaging were completed as described in the Visium protocol (SI Appendix, Methods). Each spot captures mRNA from 1 to 10 individual cells at that tissue location. (B) Delineation of scar layers based on underlying tissue histology at each timepoint (Top row), and UMAP plot showing that the three scar layers can easily be distinguished by their transcriptional programs, even independent of spatial information. (C) (i) Schematic of classic stages of wound healing evaluated at POD 2, 7, and 14 relative to uninjured skin. (ii) Keratinocyte activity as measured through expression of the Krt6b gene. (iii) Fibroblast activity as measured through expression of the Pdgfra gene. (iv) Immune cell activity as measured through expression of the Msr1 gene. (D) Anchor-based integration of scRNA-seq populations (defined in Fig. 2B) with Visium gene expression to project partial membership within each spot across all timepoints. These populations exhibit strong spatial preferences within the wound.

The epidermal, dermal, and hypodermal layers of the healing wounds were easily delineated histologically and also found to cluster independently based on transcriptional programs (Fig. 4B). Looking at individual genes for prominent wound healing cell types (Fig. 4 C, i), we found clear delineation of keratinocytes in the epidermis based on Krt6b expression (as well as other keratinocyte-specific genes), allowing us to examine reepithelialization over space and time at the transcriptional level (Fig. 4 C, ii). Similarly, fibroblast activity was evaluated using characteristic genes such as Pdgfra, which were most prominent in the dermis and most active at POD 14 (Fig. 4 C, iii). Likewise, by examining activated macrophage markers like Msr1, we could monitor these immune cells throughout our dataset and found that they were very prominent in the proud flesh at the center of the wound at POD 7 (Fig. 4 C, iv).

One challenge inherent in current spatial transcriptomic platforms such as Visium is that each spot (i.e., discrete spatial subregion from which transcripts are sequenced) can capture gene expression information from more than one cell (1 to 10 cells, characteristically). In a complex tissue such as a healing wound, this often includes cells of different types, particularly within the dermis where fibroblasts, multiple types of immune cells, and nascent blood vessels can be found. As such, to understand our spatial transcriptomics results in the context of our scRNA and scATAC fibroblast data, we needed to account for the contributions of nonfibroblast cells from each Visium spot. This was achieved by first estimating the number of each specific cell type present within individual spots based on the associated histological staining (SI Appendix, Figs. S12 AD and S13). Cell counting was followed by random sampling in a Monte Carlo fashion to subtract out potential contributions from nonfibroblast cells, generating a distribution of 10,000 inferred fibroblast transcriptomes for each Visium spot. These were propagated forward for anchor-based integration to generate and pool spatially overlaid partial memberships for each of our four scRNA-clusters (Fig. 4D).

We found that the predicted spatial distributions for our scRNA-seq clusters were largely congruent with the transcriptional differences observed earlier between inner and outer cells using our microdissection approach (e.g., fibroblasts belonging to the mechanofibrotic cluster became more prominent over time, expanding from the outer to inner wound regions to fill the scar). Upon further examining transcriptional programming relative to tissue depth, we observed clear spatial distinctions between the apical and basal regions of the dermis as early as POD 7 and most prominently at POD 14 (SI Appendix, Figs. S14 AF and S15 A and B). For example, the MMP inhibitor Timp1 is expressed by fibroblasts in the basal dermis, while Thbs2, which mediates cellmatrix interactions, is primarily expressed in the more apical scar region.

To assess the relative differentiation states of fibroblasts in this system, we applied CytoTRACE to our POD 14 dermal scar data and found that, similar to our RNA-seq microdissection findings, fibroblasts exhibited significantly less transcriptional diversity in inner wound regions, further supporting fibroblast differentiation from the outer to the inner wound regions during tissue repair (SI Appendix, Fig. S16).

To further explore fibroblast cell fate with spatial resolution, we developed a method to combine our integrated single cell RNAATAC framework with Visium in order to impute spatially informed epigenomes for wound healing fibroblasts (Fig. 5A). As described above, we generated spatial transcriptomic data from unwounded skin and POD 2, 7, and 14 wounds. To extend this analysis to impute spatial epigenomic properties, we used our RNAATAC construct to ascribe partial membership values to fibroblasts present within each Visium spot. This was achieved by first subtracting out putative nonfibroblast contributions as described above, followed by anchor-based mapping into a higher-dimensional cluster space from our gene integration matrix (Fig. 5B and SI Appendix, Table S1). Parameterization was optimized to preserve spatial autocorrelation for the top measured and imputed gene expression distributions within the POD 14 dermis (SI Appendix, Fig. S17 A and B). To account for residual contributions from nonfibroblast cells that may remain after our initial subtraction step, we also spiked in RNA-seq data for keratinocytes, endothelial cells, macrophages, and neutrophils. The resulting putative reference matrix was then used to assign initial partial set memberships for each spatial datapoint using an anchor transferbased approach. A single-step spatial smoothing filter was applied to this membership space, followed by removal of nonfibroblast contributions and renormalization. The resulting partial set memberships for each spatial datapoint then allowed us to project higher-order epigenomic features from the scRNAATAC data onto these Visium samples (SI Appendix, Fig. S18 AD). These spatial epigenomic imputations provided a valuable complement to further refine our understanding of the fibroblast biology driving tissue repair. Detailed data analysis is provided in Fig. 5 C and D and SI Appendix, Figs. S19 and S20 and more broadly summarized below for each timepoint in the healing process.

Integrated analysis permits imputation of spatial epigenomic properties. (A) Punnett square schematic summarizing the data acquired in Figs. 2 and 4; setting the stage for imputation of spatial epigenomics. (B) Schematic summarizing imputation of spatial epigenomics. Multimodal scRNAATAC fibroblast data were first reclustered into a higher-resolution space to generate 20 partitions, each representing between 27 and 552 cell equivalents. Gene score matrix distributions, informed by both modalities, were then extracted for each partition and subjected to SCT transformation. Spike-in RNA-seq data for keratinocytes, endothelial cells, granulocytes, and macrophages were obtained from pure Visium spots across all timepoints. These data were combined and subjected to a similar variance-stabilizing transformation. The resulting putative single-cell gene expression reference matrix was then used to assign initial partial set memberships for each spatial transcriptomic datapoint using an anchor transferbased approach. Nonfibroblast contributions were subsequently regressed out, and a single-step spatial smoothing filter was applied to the resulting membership space, followed by renormalization. The resulting partial set memberships for each spatial datapoint were then treated as a topological vector space, onto which epigenomic peak, motif, and binding activity from the 20 scRNAATAC partitions can be projected. (C) Visium plots showing POD 0, 2, 7, and 14 (Top to Bottom) wound sections, imputed spatial epigenomics. For housekeeping genes such as Hprt (Top), gene imputed matrix (GIM) correlates with gene score matrix (GSM) epigenomic data and is fairly stable over space and time (Top). However, for Runx1, which we have shown to be very active within wound fibroblasts, GSM data show opening at the Runx1 motif at POD 2, which yields strong gene expression primarily among inner wound fibroblasts at POD 7 (Bottom). (D) Visium plots showing POD 0, 2, 7, and 14 (Top to Bottom) wound sections, motif deviations for genes of interest related to FAK-mediated mechanotransduction, and fibroblast proliferation including Runx1, Ets1, and Ehf.

Immediately following wound injury, tissue trauma leads to inflammatory cell recruitment, provisional clot formation, and a dermal gap resulting in loss of contact inhibition among local fibroblasts. These fibroblasts are recruited into the wound bed and begin proliferating. Our data suggest that by POD 2, subsets of these cells have differentiated along the wound margin to form a putative Activated-Responder Fibroblast subpopulation. Other, less-differentiated and more mechanosensitive (mechanofibrotic), fibroblasts become preactivated in the deeper dermis at this point, increasing chromatin accessibility for Runx1, which is a primary regulator of mesenchymal progenitor cell proliferation and differentiation (33).

By POD 7, macrophage-dominated granulation tissue occupies the central wound defect, allowing overlying keratinocyte proliferation and reepithelialization. At this time, mechanofibrotic Fibroblasts begin to differentiate as they finish migrating toward the wound center, where they appear to transition to a more Proliferator subpopulation. These cells are strongly profibrotic and characterized by elevated Spp1 gene expression and chromatin accessibility. In parallel, a population of Remodeling Fibroblasts begins to appear in the outer deep dermis (Fig. 4 C and D and SI Appendix, Fig. S15 A and B).

At POD 14, reepithelialization is complete, and the wound is traditionally considered to be healed. However, while keratinocyte activity does decrease at this time (consistent with completion of reepithelialization), there remains a strong immune cell presence, supported by continued wound fibroblast chemokine secretion, to stimulate active fibrosis in the dermal layer (SI Appendix, Fig. S14 E and F).

Considering our imputed spatial epigenomics data more globally, we observed that changes to chromatin accessibility frequently preceded downstream changes in gene expression, even within the constraints of our coarse temporal sampling (Fig. 5 C and D and SI Appendix, Fig. S19 AC). For example, we found that the Runx1 motif, which is downstream from and regulated by FAK mechanotransduction, initially becomes open at POD 2, remains open particularly along the leading wound edge at POD 7, and then begins to decrease in accessibility throughout the nascent scar at POD 14. Similarly, Col1a2 motif opening precedes a dramatic increase in Col1a2 gene expression seen in the POD 14 wound scar.

In aggregate, these studies represent a framework for the comprehensive elucidation of wound healing fibroblast phenotypes based on both gene expression and chromatin accessibility across time, space, and lineage. Furthermore, these findings allow us to reevaluate the classical stages of wound healing, typically described as three overlapping phases: inflammation (POD 2), proliferation (POD 7), and remodeling (POD 14) (3). Based on our findings, we propose reframing these overlapping stages as: 1) Early inflammation, in which immune cells are migrating and infiltrating the injury site without proliferation; 2) reepithelialization, which includes rapid keratinocyte proliferation across the wound surface, fibroblast recruitment, and macrophage proliferation; and 3) activated fibrosis, where maximal fibroblast activation is achieved and sustained in a slow asymptotic decay by steady-state inflammatory signaling beneath the healed wound (SI Appendix, Figs. S21 AD and S22 A and B).

In this manuscript, we define fibroblast biology throughout the course of wound healing using integrated, single-cell multimodal -omics to unravel the spatial, temporal, and functional heterogeneity of these cells. We demonstrate that fibroblasts are activated from tissue-resident cells in response to injury and proliferate polyclonally to fill the wound gap. Furthermore, we demonstrate that fibroblasts undergo spatially informed differentiation during this process.

Elucidating these relationships required the integration of nascent technologies and data platforms in what is still a rapidly evolving field of multiomic imputation. This work demonstrates the paired analysis of single-cell RNA and chromatin accessibility with spatial resolution in the context of tissue repair. This approach provides a unique lens through which we can view complex cell processes, and specifically allowed us to demonstrate that upstream chromatin changes surrounding mechanical signaling elements precede transcriptional activation and cell proliferation, thus suggesting a mechanistic link from tissue force to activation of wound healing fibroblasts.

Furthermore, we were able to identify and characterize putative, functionally distinct fibroblast subpopulations with divergent transcriptional and epigenomic programs. We provisionally designate these four wound healing fibroblast phenotypes as Mechanofibrotic, Activated Responder, Proliferator, and Remodeling. Following skin injury, fibroblasts are locally recruited and migrate to the wound. By POD 2, a subset of fibroblasts appears to have differentiated to form an activated-responder subpopulation, while the remaining outer wound fibroblasts comprise the less differentiated mechanofibrotic cells. The latter fibroblasts highly express known fibrosis-associated markers such as Engrailed-1 (23, 24), Col1a1 (34), Tgbf2 (35), and Jun (36). At POD 7, mechanofibrotic cells begin to differentiate in response to mechanotransduction cues as they migrate toward the wound center. By POD 14, despite complete epithelialization, healed wounds remain in a steady state of fibrosis, maintained through sustained inflammatory signaling within scar tissue. Additional studies examining even later timepoints will be required to further characterize the dynamics of these cells within the healed scar tissue.

Taken together, these results illustrate fundamental principles underlying the cellular response to tissue injury. We demonstrate that populations of fibroblasts migrate, proliferate, and differentiate in an adaptive, dynamic response to disruption of their local mechanical environment. Understanding the origin, activation, and differentiation trajectories of injury-responsive cells is critical to develop therapeutic strategies to promote optimal tissue repair.

Read more:
Integrated spatial multiomics reveals fibroblast fate during tissue repair - pnas.org

Faster healing of wounds can decrease pain and suffering and save lives – WSAZ-TV

Published: Oct. 4, 2021 at 4:02 PM EDT|Updated: 23 hours ago

ORLANDO, Fla., Oct. 4, 2021 /PRNewswire/ --Billions of dollars are spent every year because of complications of wound healing. Researchers at the College of Medicine at the University of Central Florida (UCF) in Orlando have discovered a new technology to accelerate wound healing. Their research is published in the Life Cell Biology and Tissue Engineering Journal (https://pubmed.ncbi.nlm.nih.gov/34575027/). The UCF lab's research focus is to develop stem cell therapies for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, wound healing and ALS.

Researchers at the College of Medicine at UCF in Orlando have discovered a new technology to accelerate wound healing.

Dr. Frederick R Carrick, Professor of Neurology at the College of Medicine at UCF, reported that animals with wounds and injured stem cells that were placed on a special ceramic blanket healed much faster than controls. Gladiator Therapeutics manufactured the therapeutic ceramic blanket that was used in this research. The researchers reported that wounds in animals and in stem cells were both repaired significantly faster when they treated them with the ceramic blankets.

This research was designed and accepted for presentation at the USA Department of Defense's premier scientific meeting, the Military Health System Research Symposium (MHSRS). Dr Carrick stated that the new ceramic blankets do not need a power supply and are ideally suited for use in both combat and civilian wound treatments. Large wounds, such as those suffered in combat are easily infected and may result in increased suffering, disability and death amongst Warfighters. Faster healing of wounds can decrease pain and suffering and save lives.

The UCF College of Medicine research team is conducting ongoing research on the use of the Gladiator ceramic blanket in animal models of Alzheimer's and Parkinson's disease, traumatic brain injury and wound care. They have recently developed a new Alzheimer's therapy combining drugs that affect stem cells that increase the development of brain cells and improve brain function. The UCF lab is also the first to transplant stem cells isolated from the human brain to aged rats where they showed increased development of new brain cells and improvement of cognition.

Dr. Kiminobu Sugaya, Professor of Medicine at the UCF College of Medicine is excited about their findings. Dr. Sugaya stated that the benefits of using the Gladiator ceramic blanket are that it can be used anywhere without a power supply or the side effects that are commonly found when injecting chemicals or drugs.

Further information about this study:

drfrcarrick@post.harvard.edu 321-868-6464

View original content to download multimedia:

SOURCE University of Central Florida College of Medicine

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Read the original here:
Faster healing of wounds can decrease pain and suffering and save lives - WSAZ-TV

October: Henrietta Lacks statue | News and features – University of Bristol

A life-size bronze statue of Henrietta Lacks, a Black American woman whose cells were the first ever to survive and multiply outside the body, and whose use changed the course of modern medicine, has been unveiled at the University of Bristol by members of her family to honour the 70th anniversary of her cells first being used.

Her sonLawrence Lacks, who was 17 when his mother passed away,was joined by her grandson Alan Wilks and his wife Pam, granddaughter Jeri Lacks-Whye and great-granddaughters Victoria Baptiste and Veronica Robinson for the unveiling this afternoon Monday 4 October 2021.

The statue,commissioned by the University earlier this year,is located inthe heart of thecampusprecinct next to Royal Fort House. It is thework of Bristol artist HelenWilson-Roeand is the first public statue of a Black woman made by a Black woman to be permanently installed in the UK.

It follows the exhibiting of two of Helens portraits of Henrietta Lacks and Cllr Cleo Lake, Bristols first Black female Lord Mayor, which have been on display in the Wills Memorial Buildingsince October2020.

Henrietta Lacks wasa young wife and motherwhodiedin 1951of an unusually aggressive form of cervical cancer. During surgery, a sample of cells was taken from the tumour and was sent to a laboratory where they were found to be thefirst living human cells ever to survive and multiply outside the human body.Henriettas cells weretaken without her or her family's knowledge or consent,and it was only in 1975 that by chance the family found out about her legacy.

Because Henriettas cells were able to proliferate indefinitely, they formed the first scientifically definedimmortalhuman cell line, opening the door to all kinds of experiments and research on cell behaviour.

These cells madepossible some of the most important medical advances of all time including the development of the polio vaccine, chemotherapy, gene-mapping, IVF and cloning.

They became known as HeLa cells - taking the first two letters of Henriettas first and last names. HeLa cells are used in almost every major hospital and science-based University in the world, including the University of Bristol where they have been used most recently, for COVID-19 research.

The Universitys Faculty of Life Sciences has been working with students and staff to look at how it can diversify its teaching curriculum with one focus being to highlight previously overlooked figures which will include Henrietta Lacks and the important ethical issues and debates that are part of her story.

The University is also announcing the launch of The Henrietta Lacks Studentship - a six-week paid summer internship for an undergraduate student to work in its laboratories on cell biology and, with the support of the Lacks Family, is planning free in-person visits to the University for KS4 and KS5 pupils to learn more about cell biology. Other education science events in collaboration with the Lacks family both in the UK and overseas are underway.

The University is collaborating with the Lacks family-ledHELA 100: The Henrietta Lacks Initiative, which began during her centennial year and features aworldwide education and advocacy tour. The statue unveiling will also be live streamed around the world as part of the HELA100 Colloquium, commemorating 70 years since Henriettas incredible HeLa cells changed the world and her untimely death on 4 October 1951.

Attendees will learn about the worldwide advancements made bythe cellsand Henriettas descendants to educate future generations on the impact of her immortal HeLa cells while promoting health equity and social justice.

Jeri Lacks-Whye, Henrietta Lacks Granddaughter, said:As the worldcommemorates 70 years since Henrietta Lacks HeLa cells changed the world,we also reflect on my grandmother's untimely passing. It is only fitting that she be memorialised to educate future generations on her legacy and the importance of advancing health equity and social justice for all. The Lacks Family is honoured to begin our HELA100 worldwide tour with the University of Bristol and Helen Wilson Roe for the unveiling of this historic statue.

Helen Wilson-Roe said: Henriettas statue will be the first public statue of a Black woman made by a Black woman in the UK and will be installed permanently on the University of Bristol campus. May our ancestors continue to show us the way to walk.

As a child growing up in Bristol there were no statues of Black women that I could identify with.So,knowing that my children and their grandchildren and great grandchildren will be able to see Henrietta's statue, is just fantastic, especially at this time when Bristol is starting to address its past.

I have been researching about Henrietta Lacks independently for over 20 years. My mission now is to finish painting all 24 portraits of the Lacks family and gift the portraits to the family so that they retain full control of their legacy.

Professor Jeremy Tavare, Dean of theFaculty of Life Sciencesat the University of Bristol,who is also a biochemist,added: Many of our biomedical science researcherswhose work uses human cellshave used Henriettas cells in their research or with collaborators, including myself.We all owe Henrietta an enormous debt of gratitude.

I am absolutely delighted to be able to host this beautiful statue of Henrietta on our campus so we can visually honour her contribution to important discoveries we have made in Bristol over the last 70 years. I feel intensely proud that her family have been so supportive in our doing so. Her statue will do so much to raise her profile with our students and also with children in our local communities.

Professor Judith Squires, Deputy Vice-Chancellor and Provost, said: Henrietta Lacks legacy to science research and health care globally cannot be underestimated.Thisstatuecelebratesthe impact her cells have made to our research here in Bristol, and indeed research around the world.

The Lacks family have a unique relationship with Helen Wilson-Roe, who is a local artist and wished for her statue to be in Bristol.We are pleased to be able to give it a permanent home right here on our campus.

The statue also marks a significant step in addressing the lack of representation of women, and women of colour, in public artwork in our diverse multicultural city. As public art, the local community are most welcome to visit to see this wonderful statue for themselves and learn more about Henrietta Lacks and her legacy.

Read more about Henrietta's story here.

About HELA100: The Henrietta Lacks Initiative

August 1, 2020, Henrietta Lacks100th birthday, marked the launch of The Lacks Family-led year-long HELA100: Henrietta Lacks Centennial CELLebration. In honor of Henrietta Lacks101st birthday, The Lacks Family announced the advancement of their philanthropic effort HELA100: The Henrietta Lacks Initiative. This year HELA100 commemorates 70 years since Henrietta Lacks HeLa cells changed the world and her untimely death on October 4, 1951. HELA100 educates future generations on the impact of Henrietta Lacks HeLa cells while promoting health equity and social justice. Learn more at hela100.org

See the original post:
October: Henrietta Lacks statue | News and features - University of Bristol

EMBL and University of Tartu sign MoU to boost scientific collaboration – Science Business

Since June 2019, Estonia has been a prospect member state of the European Molecular Biology Laboratory (EMBL). A memorandum of understanding (MoU) has now been signed between EMBL and the University of Tartu, a leading centre of research and training. The MoU aims to strengthen cooperation between EMBL and the life science research community in Estonia, building on the very successful links in the context of the prospect membership.

This MoU also formalises previous exchanges and research collaborations between the two institutions. In February 2021, EMBL and the Estonian Research Council organised a joint workshop in which many Estonian researchers were actively involved, including participants and speakers from the University of Tartu. On this occasion, EMBL Director General Edith Heard presented the next EMBL Programme, Molecules to Ecosystems, which has the aim of understanding life in its natural context. EMBLs scientific plans for the next five years (20222026) is the first pan-European molecular biology programme for environmental and human health and has collaboration across disciplines and sectors at its core.

Confronted with global challenges and urgent societal and environmental needs, fostering cooperation and integrating European life science have become essential endeavours. Estonia has been a very engaged prospect member of EMBL since 2019, and I view the signing of the MoU with the University of Tartu as a catalyst for collaboration between the two organisations, says Edith Heard. The MoU stands as a firm commitment to enhancing cutting-edge scientific research, knowledge sharing, and training, especially in the context of the new EMBL Programme. This will benefit Estonias life science landscape as we prepare for the countrys accession to EMBL as a full member state.

During the workshop in February, EMBL Deputy Director General Ewan Birney highlighted the work of EMBLs European Bioinformatics Institute (EMBL-EBI) in human genetics and personalised medicine. Other talks by EMBL Heads of Faculty touched upon bioinformatics training opportunities and some of the themes in the new EMBL Programme. Possibilities for joint collaboration were also discussed, particularly on several of the programmes new transversal themes, such as Human Ecosystems, Planetary Biology, Microbial Ecosystems, and Data Science.

Estonia has shown great success in attracting talent, so we really look forward to collaborating with all those excellent researchers. Im thrilled to see what discoveries come from this exciting new alliance says Ewan Birney.

This formalised collaboration between EMBL and the University of Tartu is already helping to forge stronger links between EMBL and the science landscape in Estonia. Estonian researchers have had individual contacts with EMBL, but through the MoU we are now committed to advance the joint undertakings at more systematic and strategic levels to help to boost the career of young Estonian talent, further the development of joint scientific infrastructures and increase the overall volume of interactions and activities both in experimental biology as well as biological data management and analysis, says Jaak Vilo, one of the EMBL Council delegates from Estonia and current Head of the Institute of Computer Science at the University of Tartu.

Toivo Maimets, Professor of Cell Biology at the University of Tartu and former president of the European Molecular Biology Conference (EMBC)* of which Estonia has been a member since 2006, sees the MoU between the University of Tartu and EMBL as the next important step to carry on the rapid developments of Estonian science. Tighter collaboration between the EMBL and our university will accelerate our full membership in EMBL and bring even more possibilities to gain from these top-level international professional networks, says Maimets.

*The European Molecular Biology Conference (EMBC) is an intergovernmental organisation that provides a framework for European cooperation in the field of molecular biology and closely-related research areas.

This article was first published on October 4 by University of Tartu.

The rest is here:
EMBL and University of Tartu sign MoU to boost scientific collaboration - Science Business

Mantarray: Scalable Human-relevant 3D Engineered Cardiac and Skeletal Muscle Tissues for Therapeutics Discovery Upcoming Webinar Hosted by Xtalks -…

Learn how these advanced 3D tissue models generated on the Mantarray platform can improve the physiological relevance of preclinical cardiac and skeletal muscle models, accelerating the discovery of new medicines.

TORONTO (PRWEB) October 05, 2021

3D cellular models and organs-on-chips are poised to add tremendous value by providing human data earlier in the drug discovery pipeline. There is intense interest in adopting these 3D models in preclinical and translational research, but their complex implementation has remained a roadblock for many labs.

In this webinar, Curi Bio will present its Mantarray platform, which represents an easy-to-use, flexible, and scalable system for generating 3D EMTs at high-throughput with the ability to measure contractility in parallel. The platform features a novel method of casting 3D tissues that can be easily performed by nearly any cell biology researcher and can be readily adapted to a variety of cell lines and extracellular matrices. In addition, Mantarrays novel magnetic sensing modality permits contractility measurement of 24 tissues in parallel and in real time, while the cloud data analysis portal takes the guesswork out of analyzing and comparing results across experiments.

Register for this webinar to hear an overview of the technology, along with application examples across various use cases, including:

Learn how these advanced 3D tissue models generated on the Mantarray platform can improve the physiological relevance of preclinical cardiac and skeletal muscle models, accelerating the discovery of new medicines.

Join Dr. Nicholas Geisse, Chief Science Officer at Curi Bio, for the live webinar on Friday, October 22, 2021 at 1pm EDT.

For more information, or to register for this event, visit Mantarray: Scalable Human-Relevant 3D-Engineered Cardiac and Skeletal Muscle Tissues for Safety and Efficacy Studies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.comFor information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

Read the rest here:
Mantarray: Scalable Human-relevant 3D Engineered Cardiac and Skeletal Muscle Tissues for Therapeutics Discovery Upcoming Webinar Hosted by Xtalks -...

Gene Identified in Mice and Monkeys Acts as Natural Antiviral Against HIV, Ebola, and Other Deadly Infections – Genetic Engineering &…

A research team led by scientists at the University of Utah (U of U) Health and the Rockefeller University has determined how a genetic mutation found in mice and in some New World monkeys interferes with how viruses such as HIV and Ebola infect cells. The gene, called RetroCHMP3, encodes an altered protein that disrupts the ability of certain viruses to exit an infected cell, and so prevents it from going on to infect other cells. The researchers suggest that the finding could help inform the future development of strategies for human therapeutics.

This was an unexpected discovery, said Nels Elde, PhD, senior author of the study and an evolutionary geneticist in the department of human genetics at U of U Health. We were surprised that slowing down our cell biology just a little bit throws virus replication off its game.

The team reported its findings in Cell, in a paper titled, RetroCHMP3 blocks budding of enveloped viruses without blocking cytokinesis.

In humans and other animals, a protein called charged multivesicular body protein 3, or CHMP3, is well known for playing a key part in cellular mechanisms that are vital for maintaining cellular membrane integrity, intercellular signaling, and cell division. The endosomal sorting complexes required for transport (ESCRT) pathway mediates essential cellular membrane fission events such as multivesicular body formation, cytokinetic abscission, and resealing of the post-mitotic nuclear envelope, the authors explained. Some viruses, including HIV, which are known as enveloped viruses, hijack this ESCRT pathway to exit infected cells, which they do by encasing themselves in the cell membrane and then budding off from the host cell.

The new study has found that the variant version of CHMP3, known as RetroCHMP3, which is found in monkeys and mice, delays that process long enough that the virus can no longer escape. RetroCHMP3 originated as a duplicated copy of CHMP3. So while humans only have the original CHMP3, species such as monkeys, mice, and other animals, have retroCHMP3 or other variants.

Based on their research, Elde and his colleagues suspected that the duplications of CHMP3 that they discovered in primates and mice blocked the ability of enveloped viruses to co-opt the ESCRT pathway into their escape mechanism, as protection against viruses like HIV and other viral diseases.

Building on their hypothesis, Elde and other scientists began exploring whether variants of CHMP3 might work as an antiviral. In laboratory experiments conducted elsewhere, a shorter, altered version of human CHMP3 successfully prevented HIV from budding off cells. There was, however, a glitch: the modified protein also disrupted important cellular functions, causing the cells to die.

Unlike other researchers, Elde and his colleagues at U of U Health had naturally occurring variants of CHMP3 from other animals available. So, working in collaboration with Sanford Simon, PhD, co-author and professor of cellular biophysics at the Rockefeller University, along with Phuong Tieu Schmitt, PharmD, research associate and Anthony Schmitt, PhD, professor of molecular virology, both at Pennsylvania State University, they tried a different approach.

Using genetic tools, they coaxed human cells to produce the version of retroCHMP3 found in squirrel monkeys. When they then infected the cells with HIV, they found that the virus had difficulty budding off from the cells, essentially stopping them in their tracks. When expressed in human cells, these retroCHMP3 proteins potently inhibit the release of retroviruses, paramyxoviruses, and filoviruses, the investigators wrote. And this occurred without disrupting metabolic signaling or related cellular functions that can cause cell death. Remarkably, retroCHMP3 proteins have evolved to reduce interactions with other ESCRT-III factors and have little effect on cellular ESCRT processes, revealing routes for decoupling cellular ESCRT functions from viral exploitation, the team noted.

The scientists also suggested that an antiviral approach based on exploiting retroCHMP may prove more durable than existing antiviral strategies. Additionally,the observation that retroCHMP3 alters ESCRT pathway function instead of targeting a viral protein raises theintriguing possibility that retroCHMP3 may be more resistant to viral counter-adaptations than other antiviral proteins that directly inhibit viral replication, they stated.

Were excited about the work because we showed some time ago that many different enveloped viruses use this pathway, called the ESCRT pathway, to escape cells, said Wes Sundquist, PhD, co-corresponding author of the study and chair of the department of biochemistry at the University of Utah. We always thought that this might be a point at which cells could defend themselves against such viruses, but we didnt see how that could happen without interfering with other very important cellular functions.

From an evolutionary perspective, Elde believes this represents a new type of immunity that can arise quickly to protect against short-lived threats. We thought the ESCRT pathway was an Achilles heel that viruses like HIV and Ebola could always exploit as they bud off and infect new cells, Elde said. RetroCHMP3 flipped the script, making the viruses vulnerable. Moving forward, we hope to learn from this lesson and use it to counter viral diseases.

More specifically, that lesson raises the possibility that an intervention that slows down the process may be inconsequential for the host, but provide us with a new anti-retroviral, added Simon.

View post:
Gene Identified in Mice and Monkeys Acts as Natural Antiviral Against HIV, Ebola, and Other Deadly Infections - Genetic Engineering &...

Study reveals the underlying mechanisms behind obesity and type 2 diabetes link – News-Medical.Net

It is well known that obesity affects the body's insulin production and over time risks leading to type 2 diabetes and several other metabolic diseases. Now researchers at Karolinska Institutet in Sweden have found further explanation for why fat cells cause metabolic morbidity. The study, published in Nature Medicine, may have an impact on the treatment of comorbidity in obesity with already available drugs.

Obesity is a rapidly growing global public health problem, not least among children and young people. Many metabolic diseases, among them type 2 diabetes, are strongly associated with obesity. In order to reverse the trend, more knowledge is needed, among other things, about how fat cells (adipocytes) contribute to various harmful processes in tissues and organs.

When fat cells are enlarged, they begin to secrete factors that cause inflammation of the adipose tissue. Fat cell enlargement is also associated with insulin resistance, when cells in the body do not respond to insulin as they should. The important task of insulin is to regulate energy, glucose, for the body's cells. When that function is disturbed, as with insulin resistance, the risk of type 2 diabetes increases.

This relationship is well documented, but there has been a lack of knowledge about the underlying mechanisms behind enlarged fat cells (fat cell hypertrophy) and the secretion of pro-inflammatory substances.

Now researchers at Karolinska Institutet have shown that in obesity and insulin resistance, the cell activity of fat cells changes. As fat cells increase in cell size, nuclear size and nuclear DNA content also increases.

The process of cells not dividing but increasing in DNA content and cell size (endoreplication) is common among plants and animals. In contrast, the process has not been described for human fat cells (adipocytes), which can increase in size more than 200 times over their lifespan."

Qian Li, Researcher, Department of Cell and Molecular Biology, Karolinska Institutet, and Joint First Author

The natural process of fat cells increasing in size has several negative effects on health. The authors demonstrate that elevated levels of insulin in the blood cause premature aging, senescence, in some cells in the adipose tissue.

"Our results show that senescent fat cells increase the secretion of pro-inflammatory factors, and drive inflammation and pathology in human adipose tissue. This in turn affects the health of the whole body," says Carolina Hagberg, researcher at the Department of Medicine, Solna at Karolinska Institutet, and joint first author.

The results are based on analysis of adipose tissue from 63 people with BMI under 30 who underwent umbilical hernia surgery or cholecysectomy for gallstone disease, as well as 196 people with BMI over 30 who underwent bariatric surgery for obesity in Stockholm.

Using a commonly prescribed drug for type 2 diabetes, the researchers were able to block the formation of senescent fat cells and reduce the secretion of fat cell-based pro-inflammatory factors.

"These studies identify an unappreciated aspect of human adipocyte biology, the activation of a cell cycle program in obesity and hyperinsulinemia, which could pave the way for novel treatment strategies for obesity and associated co-morbidities, such as type 2 diabetes," says Kirsty Spalding, researcher at the Department of Cell and Molecular Biology, Karolinska Institutet, and the study's last author.

Source:

Journal reference:

Li, Q., et al. (2021) Obesity and hyperinsulinemia drive adipocytes to activate a cell cycle program and senesce. Nature Medicine. doi.org/10.1038/s41591-021-01501-8.

See original here:
Study reveals the underlying mechanisms behind obesity and type 2 diabetes link - News-Medical.Net

Aging-US: Cellular senescence in lymphoid organs and immunosenescence – EurekAlert

image:With advancing age, the stromal cells in the lining of sinuses, that demarcate follicular zone from the marginal zone, become less organized accompanied with an altered localization of various cell types. The inflammatory environment created by the accumulation of SnCs impairs the functionality of several cells residing in the spleen. This functional impairment mediated improper antigen presenting capabilities lead to the establishment of an inadequate T-cell response against pathogenic invasion. Abbreviations: SnC: Senescent cell; SASP: Senescence associated secretory phenotype; ROS: Reactive Oxygen Species. view more

Credit: Correspondence to: Daohong Zhou email: zhoudaohong@cop.ufl.edu

Aging-USpublished "Cellular senescence in lymphoid organs and immunosenescence" which reported that immunosenescence is a multi-faceted phenomenon at the root of age-associated immune dysfunction.

Though both cellular senescence and immunosenescence have been studied extensively and implicated in various pathologies, their relationship has not been greatly explored. In the wake of an ongoing pandemic that disproportionately affects the elderly, immunosenescence as a function of age has become a topic of great importance.

The goal of this review is to explore the role of cellular senescence in age-associated lymphoid organ dysfunction and immunosenescence, and provide a framework to explore therapies to rejuvenate the aged immune system.

Dr. Daohong Zhou fromThe University of Floridasaid, "Aging is the gradual process of organismal deterioration which is associated with a multitude of age-related disorders and diseases that make one wonder if aging itself is a disease that needs to be addressed."

A shadow is cast on the benefits of longevity if the elderly are faced with the possibility of a decline in their quality of life. The world currently has over 700 million people who are over the age of 65, a number that is projected to grow rapidly in the near future. As advancing age is strongly correlated to decreased quality of life and increased risk of several age-related diseases, these demographics seem more dismal in prospering countries, with the USA and the UK having about 1618% of their population over the age of 65.

The silver lining to this otherwise tragic situation is that results from recent studies indicate that the aging process and the pace of organismal deterioration is malleable and can be influenced greatly by physiological, genetic, dietary and pharmaceutical interventions.

The Zhou Research Team concluded in theirAging-US Research Output, "The increasing array of genetic models of SnC clearance along with a growing panel of senolytic and senostatic agents, provide a unique opportunity for scientists to answer these questions to lay a strong foundation to this new avenue of research in immunosenescence. Ultimately, gaining a deeper understanding of the interaction between cellular senescence and immunosenescence will help in the development of improved therapeutics that will aid in the conservation of our vitality as we age."

Full Text -https://www.aging-us.com/article/203405/text

Correspondence to: Daohong Zhouemail:zhoudaohong@cop.ufl.edu

Keywords:cellular senescence,immunosenescence,immune senescence,senescence associated secretory phenotype (SASP),thymus

About Aging-US

Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research as well as topics beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, cancer, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR among others), and approaches to modulating these signaling pathways.

To learn more about Aging-US, please visithttp://www.Aging-US.comor connect with@AgingJrnl

Aging-US is published byImpact Journals, LLCplease visithttp://www.ImpactJournals.comor connect with@ImpactJrnls

Media Contact18009220957x105MEDIA@IMPACTJOURNALS.COM

Cellular senescence in lymphoid organs and immunosenescence

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Here is the original post:
Aging-US: Cellular senescence in lymphoid organs and immunosenescence - EurekAlert

Study: Gene therapy can restore vision after stroke – EurekAlert

Key research finding

Most strokes happen when an artery in the brain becomes blocked. Blood flow to the neural tissue stops, and those tissues typically die. Because of the locations of the major arteries in the brain, many strokes affect motor function. Some affect vision, however, causing patients to lose their vision or find it compromised or diminished. A research team led by Purdue Universitys Alexander Chubykin, an associate professor of biological sciences in the College of Science, in collaboration with the team led by Gong Chen at Jinan University, China, has discovered a way to use gene therapy to turn glial brain cells into neurons, restoring visual function and offering hope for a way to restore motor function.

Neurons dont regenerate. The brain can sometimes remap its neural pathways enough to restore some visual function after a stroke, but that process is slow, its inefficient, and for some patients, it never happens at all. Stem cell therapy, which can help, relies on finding an immune match and is cumbersome and difficult. This new gene therapy, as demonstrated in a mouse model, is more efficient and much more promising.

We are directly reprogramming the local glial cells into neurons, Chubykin said. We dont have to implant new cells, so theres no immunogenic rejection. This process is easier to do than stem cell therapy, and theres less damage to the brain. We are helping the brain heal itself. We can see the connections between the old neurons and the newly reprogrammed neurons get reestablished. We can watch the mice get their vision back.

Chubykins research is especially important because visual function is easier than motor skills to measure accurately, using techniques including optical imaging in live mice to track the development and maturation of the newly converted neurons over the course of weeks. Perfecting and understanding this technique could lead to a similar technique reestablishing motor function. This research bridges the gap in understanding between the basic interpretation of the neurons and the function of the organs.

Purdue professors expertise

Chubykin is an expert in how neurons respond to visual experiences, as well as conditions including autism and ischemic stroke. He is affiliated with the Purdue Institute for Integrative Neuroscience and the Purdue Autism Research Center.

###

Journal name

Frontiers in Cell and Developmental Biology. The article is available online.

Funding

National Institute of Mental Health grant RF1 MH123401

Brief summary of methods

The team simulated an ischemic stroke affecting the visual centers in the brains of mice, mapping and measuring the extent of the neural and visual damage. Then, they used adeno-associated viruses to deliver NeuroD1 to glial cells in the affected part of the brain. They watched and measured as the glial cells were reprogrammed into neurons and were integrated into the visual cortex. After that, they measured the responses of these cells to visual stimulus and mapped the development of the visual cortex to measure the recovery of visual function.

Writer/Media contact: Brittany Steff, bsteff@purdue.edu

Source: Alexander Chubykin, chubykin@purdue.edu

Frontiers in Cell and Developmental Biology

Experimental study

Animals

Restoration of Visual Function and Cortical Connectivity After Ischemic Injury Through NeuroD1-Mediated Gene Therapy

18-Aug-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Follow this link:
Study: Gene therapy can restore vision after stroke - EurekAlert

NextCure Announces New Appointments to its Board of Directors – GlobeNewswire

BELTSVILLE, Md., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of Ellen G. Feigal, M.D., and Anne Borgman, M.D., to its Board of Directors.

I am thrilled to welcome two new members to NextCures Board of Directors, said Michael Richman, NextCures president and chief executive officer. Both Dr. Feigal and Dr. Borgman bring extensive experience in clinical and biopharmaceutical settings. Their insights will be valuable as NextCure continues to advance multiple clinical programs and investigate and develop new immunomedicines for cancer patients. These appointments follow the resignation of Stella Xu, Ph.D. from the board as previously announced. In addition, we would like to thank Stella Xu for her commitment and support in building NextCure.

Dr. Feigal is currently a Partner and Head of the Biologics Practice at NDA Partners LLC, a life sciences consulting and contract development organization, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. Dr. Feigal is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law. Her career includes over thirty years in clinical drug development, with roles spanning industry and academic medicine, including at the National Cancer Institute, where she served as Acting Director, Division of Cancer Treatment/Diagnosis during her tenure; Senior Vice President of Research and Development at the California Institute of Regenerative Medicine, and Executive Medical Director, global development at Amgen. She currently serves as a board member for Xencor. She earned her M.D. from the University of California, Davis, completed an internal medicine residency at Stanford University and a hematology/oncology fellowship at the University of California, San Francisco.

Dr. Borgman is currently Vice President and Global Therapeutic Area Lead, Hematology-Oncology, at Jazz Pharmaceuticals, where she is responsible for global development of the companys oncology and hematology drugs, including four marketed products. Previously, Dr. Borgman was Vice President, Clinical Research & Development, at Exelixis, where she was a Clinical Lead in the global development for cabozantinib in oncology indications including renal cell, hepatocellular and thyroid carcinoma. Earlier she was Chief Medical Officer and Vice President of Hana Biosciences (Talon Therapeutics), where she oversaw all aspects of the companys drug development operations. In addition, Dr. Borgman has worked as Associate Chief Medical Officer at KaloBios Pharmaceuticals, and she was formerly a Global Development Head at Abbott Pharmaceuticals (now AbbVie) where she was responsible for the early drug development of the PARP inhibitor, antimitotic, and Bcl-2/Bcl-XL platforms. Dr. Borgman continues clinical involvement, as a Consulting Associate Professor at Stanford University School of Medicines Stem Cell Transplant & Cell Biology program, and as a Clinical Associate at University of Chicagos Department of Pediatric Oncology and Stem Cell Research. Dr. Borgman completed her fellowship in pediatric hematology - oncology and stem cell transplant at UCLA David Geffen School of Medicine, trained in pediatrics at Texas Children's Hospital, Baylor College of Medicine, and earned her M.D. from Loyola University of Chicagos Stritch School of Medicine.

About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. http://www.nextcure.com

Cautionary Statement Regarding Forward-Looking StatementsStatements made in this press release that are not historical facts are forward-looking statements. Words such as expects, believes, intends, hope, forward and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCures plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCures actual results are described in NextCures filings with the Securities and Exchange Commission (the SEC), including NextCures most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.

Investor InquiriesTimothy Mayer, Ph.D.NextCure, Inc.Chief Operating Officer(240) 762-6486IR@nextcure.com

Read the original post:
NextCure Announces New Appointments to its Board of Directors - GlobeNewswire